Get the Stockscreener App
174.63
0.34%
0.59
After Hours:
174.80
0.17
+0.10%
Overview
News
Price History
Option Chain
Financials
Why DHR Down?
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp stock is traded at $174.63, with a volume of 3.81M.
It is up +0.34% in the last 24 hours and down -8.63% over the past month.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
See More
Previous Close:
$174.04
Open:
$175.8
24h Volume:
3.81M
Relative Volume:
0.87
Market Cap:
$123.60B
Revenue:
$24.78B
Net Income/Loss:
$3.68B
P/E Ratio:
33.75
EPS:
5.1743
Net Cash Flow:
$5.29B
1W Performance:
-2.43%
1M Performance:
-8.63%
6M Performance:
-17.71%
1Y Performance:
-11.53%
1-Day Range:
$173.26
$177.68
1-Week Range:
$172.34
$180.27
52-Week Range:
$172.34
$242.80
Danaher Corp Stock (DHR) Company Profile
Name
Danaher Corp
Sector
Industry
Phone
(202) 828-0850
Address
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-10-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Mar-14-25 | Upgrade | Stifel | Hold → Buy |
| Feb-03-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Dec-19-24 | Initiated | Guggenheim | Buy |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-31-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-18-23 | Initiated | HSBC Securities | Hold |
| Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
| Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-01-23 | Initiated | SVB Securities | Outperform |
| Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-17-22 | Resumed | Bernstein | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-11-22 | Initiated | Bernstein | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-10-21 | Reiterated | BofA Securities | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Reiterated | Goldman | Buy |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Apr-07-21 | Resumed | Robert W. Baird | Outperform |
| Mar-03-21 | Resumed | Barclays | Overweight |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-03-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Resumed | Stifel | Hold |
| Oct-28-19 | Reiterated | Needham | Buy |
| Oct-14-19 | Resumed | Credit Suisse | Outperform |
| Jul-19-19 | Reiterated | Needham | Buy |
| Jun-11-19 | Initiated | Piper Jaffray | Neutral |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Feb-25-19 | Upgrade | Janney | Neutral → Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp Stock (DHR) Latest News
Danaher Corpdeclares quarterly cash dividend of $0.40 per share payable July 31, 2026 - marketscreener.com
Masimo Corp. stockholders adopted Danaher merger agreement May 1 - MLex
Danaher to acquire Masimo (NASDAQ: MASI) in $180 per share cash deal - Stock Titan
Danaher declares $0.40 quarterly dividend payable July 31 By Investing.com - Investing.com Canada
Danaher shareholders get $0.40 a share dividend on July 31 - Stock Titan
Danaher Announces Quarterly Dividend - Benzinga
Danaher (NYSE: DHR) director exercises options and sells 1,358 shares - Stock Titan
Masimo Shareholders Approve $180 Per Share Acquisition by Danaher, Merger Expected to Close in 2026 - Minichart
Masimo shareholders give green light to $10B acquisition by Danaher - MassDevice
Masimo Shareholders Approve $9.9B Sale to Danaher - Orange County Business Journal
Masimo shareholders approve its $9.9B acquisition by Danaher - Modern Healthcare
Masimo Shareholders OK $9.9B Merger Deal with Danaher - Medical Product Outsourcing
Masimo shareholders approve $180 per share Danaher acquisition - Investing.com
Masimo Shareholders Approve Acquisition by Danaher - marketscreener.com
Masimo (NASDAQ: MASI) shareholders back $180 cash acquisition by Danaher - Stock Titan
Masimo nears Danaher sale after shareholder vote backs cash merger - Stock Titan
Investors Can Find Comfort In Danaher's (NYSE:DHR) Earnings Quality - Yahoo Finance
Danaher Corp. stock underperforms Friday when compared to competitors - MarketWatch
Masimo (MASI) 10-K/A adds governance, CEO pay terms and Danaher merger plans - Stock Titan
[144] DANAHER CORP /DE/ SEC Filing - Stock Titan
Danaher Corporation stock hits 52-week low at $174.97 By Investing.com - Investing.com UK
Danaher Corporation stock hits 52-week low at $174.97 - Investing.com
DHR Technical Analysis | Trend, Signals & Chart Patterns | DANAHER CORP (NYSE:DHR) - ChartMill
Danaher Corp. may be the smartest bet in biotech right now - MSN
Single-use Bioprocessing Market Size Advancing at 11.0% CAGR | - openPR.com
FRANKLIN RISING DIVIDENDS VIP FUND's Danaher Corp(DHR) Holding History - GuruFocus
[CERT] DANAHER CORP /DE/ Certification Filing | DHR SEC FilingForm CERT - Stock Titan
Danaher Corporation: China Headwinds Persist—But Is the Core Business Strong Enough to Offset? - Smartkarma
Danaher Corp. Stock (US2358511028): Q1 2026 Earnings Set for Release Today - AD HOC NEWS
Danaher Corporation (DHR) Announces Issuance of €3 Billion in Se - GuruFocus
Danaher Corp (DHR) Stock Price, Trades & News - GuruFocus
Vanguard reports 47.4M-share stake in Danaher (NYSE: DHR) via 13G - Stock Titan
€2.98B Danaher (NYSE: DHR) euro notes to support Masimo acquisition - Stock Titan
Danaher posts $6B quarter and raises 2026 profit outlook - Stock Titan
Is It Time To Reassess Danaher (DHR) After Recent Share Price Weakness - simplywall.st
Danaher Q1 earnings beat estimates, life sciences sales up Y/Y - MSN
Danaher to buy medical tech firm Masimo for $9.9 billion - MSN
Danaher (NYSE: DHR) director granted 231.809 phantom shares - Stock Titan
Danaher (NYSE: DHR) director defers fees into 17.248 phantom share units - Stock Titan
Danaher (NYSE: DHR) director awarded new phantom share units - Stock Titan
Danaher (DHR) director Linda Filler adds 20.121 phantom shares in deferred award - Stock Titan
Danaher (NYSE: DHR) director adds 252 phantom shares via deferred fees - Stock Titan
Danaher (NYSE: DHR) director receives 187.894 phantom share award - Stock Titan
Bulk Filtration Market Report 2026, Competitive Analysis of 3M, Eaton, Parker-Hannifin, Pentair, Merck, Danaher, Mann+Hummel - GlobeNewswire Inc.
Former Fortive CEO who led $16B-to-$25B rise joins CD&R - Stock Titan
Point of Care Diagnostics Market | Abbott Laboratories, BD, Danaher Corp, Nova Biomedical Corporation etc. - openPR.com
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
XS335208480 Bond Analysis — Key Metrics - TradingView
XS335208340 Bond Analysis — Key Metrics - TradingView
Danaher Stock Forecast: What Is Driving Market Focus - Kalkine Media
State of Michigan Retirement System Decreases Holdings in Danaher Corporation $DHR - MarketBeat
Danaher Corp Stock (DHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):